Trial Profile
A Phase I, Open-label, Randomized, 3-way Crossover Trial in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC435 and Escitalopram at Steady-state.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Simeprevir (Primary) ; Escitalopram
- Indications Depressive disorders; Generalised anxiety disorder; Hepatitis C; Obsessive-compulsive disorders; Panic disorder; Premenstrual dysphoric disorder; Social phobia
- Focus Pharmacokinetics
- Sponsors Janssen R&D Ireland
- 20 Mar 2012 Additional location (Ireland) added as reported by ClinicalTrials.gov.
- 20 Mar 2012 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
- 20 Mar 2012 Actual initiation date changed from Jun 2010 to May 2010 as reported by ClinicalTrials.gov.